SEP 02, 2020 9:48 AM PDT

Does Adjuvant Chemotherapy Really Help in a Rare Signet-ring Cell Carcinoma

WRITTEN BY: Jasper Cantrell

For many rare diseases, there is a lack of a “standard” treatment options. This is more prevalent in diverse diseases like cancer, which has hundreds of types and subtypes. One rare type of colorectal cancer, signet-ring cell carcinoma, was the subject of a new study evaluating whether or not adjuvant therapy after surgery was effective.

A team from the First Hospital of Jilin University in China wanted to know if chemotherapy was necessary after tumor-removal surgery. The team notes some studies that there is conflicting evidence supporting adjuvant chemotherapy. Considering the high expense of chemotherapy, the team wanted to make sure patients were not spending even more on unnecessary treatment.

Their study revolved around analyzing signet-ring cell carcinoma patients from the SEER database to see how effective adjuvant chemotherapy was. This database covered a large percent of the North American population, and so should be a good representation of the population. In the end, they had a balanced dataset of patients who were treated with or without adjuvant chemotherapy (chemotherapy after surgery).

The data from the SEER database was pretty clear that those patients who were given the chemotherapy had a stronger overall survival rate than those who weren’t. The adjuvant chemotherapy nearly doubled the chances of survival compared to no adjuvant chemotherapy.  

If you followed common sense, you might also conclude that chemotherapy should help get rid of cancer. However, chemotherapy has many detrimental aspects to it, from toxic side-effects to sheer cost. The conflicting evidence has prevented a “standard” treatment for signet-ring cell carcinoma. The team notes that another study, one who took data from a large patient group over 20 years, agrees with this study’s results. Considering the clear positive correlation between survival and chemotherapy in this work, I would say evidence continues to support the pro-chemotherapy side.

The study concludes, “In conclusion, our results have shown that stage II/III colorectal SRCC can gain survival benefit from postoperative adjuvant chemotherapy. This is a large population-based study to discuss adjuvant chemotherapy for patients with localized colorectal SRCC, and our present findings might be of significance for disease management and future prospective researches.”

Sources: Nature Scientific Reports, OncLiveTV

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
AUG 21, 2020
Cancer
Investigating Cancer's Metabolism for a New Drug Target
AUG 21, 2020
Investigating Cancer's Metabolism for a New Drug Target
Cancer cells are quite similar to normal cells in many ways, but it’s the small differences that really matter. On ...
SEP 02, 2020
Cancer
New contrast dyes detect cancer using tatoo ink
SEP 02, 2020
New contrast dyes detect cancer using tatoo ink
Researchers have developed new cancer detection agents in the form of contrast dyes from tattoo ink. The results of thes ...
SEP 09, 2020
Cancer
Microbubbles enhance delivery of chemotherapy drug
SEP 09, 2020
Microbubbles enhance delivery of chemotherapy drug
New research published in APL Bioengineering reports on a new technology developed by scientists at Tulane Universi ...
SEP 14, 2020
Cancer
We are too uneducated on the risks of colon cancer
SEP 14, 2020
We are too uneducated on the risks of colon cancer
A study conducted by researchers from Florida Atlantic University's Schmidt College of Medicine suggests that too ma ...
SEP 29, 2020
Cancer
Gut microbiome influences oral therapy for prostate cancer treatment
SEP 29, 2020
Gut microbiome influences oral therapy for prostate cancer treatment
Research from a team of scientists at Lawson Health Research Institute and Western University suggests that bacteria in ...
OCT 07, 2020
Cancer
Delivering Cancer Drugs to Osteosarcoma with Nanoparticles
OCT 07, 2020
Delivering Cancer Drugs to Osteosarcoma with Nanoparticles
Over the years, cancer researchers have struggled not just with drug and diagnostic design, but with drug delivery. The ...
Loading Comments...